NCT01922752View on ClinicalTrials.gov

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Solid Tumors
Interventions
DRUG

CEP-37440

"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."

Trial Locations (3)

Unknown

Teva Investigational Site 10689, Chicago

Teva Investigational Site 10687, Philadelphia

Teva Investigational Site 10686, San Antonio

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01922752 - To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter